The most common method for creating ex vivo DC vaccines for NSCLC is to separate patient autologous monocytes, turn them into DCs, and then load them with tumor-associated antigens (TAAs), like mucin 1 (MUC1), Wilms’ tumor 1 (WT1), or customized neoantigens. This evidence concerns the gene WT1 and neoplasm.